Get the Stockscreener App
400.57
0.03%
-0.12
After Hours:
400.57
Overview
News
Price History
Option Chain
Financials
Why SYK Down?
Discussions
Forecast
Stock Split
Dividend History
Stryker Corp stock is traded at $400.57, with a volume of 970.36K.
It is down -0.03% in the last 24 hours and up +1.78% over the past month.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
See More
Previous Close:
$400.69
Open:
$402
24h Volume:
970.36K
Relative Volume:
0.79
Market Cap:
$152.89B
Revenue:
$23.22B
Net Income/Loss:
$2.86B
P/E Ratio:
54.13
EPS:
7.4
Net Cash Flow:
$3.58B
1W Performance:
+1.37%
1M Performance:
+1.78%
6M Performance:
+2.43%
1Y Performance:
+20.19%
1-Day Range:
$399.31
$403.92
1-Week Range:
$396.30
$404.14
52-Week Range:
$314.93
$406.19
Stryker Corp Stock (SYK) Company Profile
Name
Stryker Corp
Sector
Industry
Phone
(269) 385-2600
Address
1941 STRYKER WAY, PORTAGE, MI
Compare SYK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
400.57 | 153.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
ABT
Abbott Laboratories
|
128.01 | 219.83B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.47 | 156.58B | 18.49B | 2.51B | 2.72B | 1.68 |
|
MDT
Medtronic Plc
|
92.44 | 117.84B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.47 | 46.04B | 5.69B | 4.15B | 623.10M | 6.95 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Resumed | Citigroup | Buy |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Outperform |
| May-30-24 | Initiated | Goldman | Neutral |
| May-22-24 | Upgrade | Needham | Hold → Buy |
| Jan-31-24 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-25-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-28-22 | Upgrade | Edward Jones | Hold → Buy |
| Jul-21-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-13-22 | Initiated | Truist | Hold |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-15-22 | Resumed | Evercore ISI | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| Jul-28-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jun-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Oct-06-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-01-20 | Downgrade | Goldman | Buy → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Hold |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-30-19 | Reiterated | BTIG Research | Buy |
| Nov-05-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-30-19 | Reiterated | BofA/Merrill | Buy |
| Jul-02-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-30-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-16-18 | Initiated | BTIG Research | Buy |
| Jun-27-18 | Initiated | Bernstein | Mkt Perform |
| Apr-27-18 | Reiterated | Stifel | Buy |
View All
Stryker Corp Stock (SYK) Latest News
Stryker launches next-generation InThrill thrombectomy system - Investing.com
Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases – Company AnnouncementFT.com - Financial Times
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott - GlobeNewswire Inc.
What factors could influence SYK's earnings in the coming quarters? - AInvest
Fund Update: BRIDGES INVESTMENT MANAGEMENT INC added 38,416 shares of STRYKER ($SYK) to their portfolio - Quiver Quantitative
Clavicle Hook Plate (Fracture Fixation, Osteotomy, Malunion) Market Outlook 2025-2034 | New Advancements Propel Growth, Synthes, Zimmer Biomet, and Stryker Lead InnovationsResearchAndMarkets.com - FinancialContent
Does Stryker Corporation stock perform well during market downturnsAchieve breakthrough financial results today - jammulinksnews.com
TD Cowen Maintains a Buy on Stryker Corporation (SYK) With a $435 PT - Insider Monkey
What are Stryker Corporation company’s key revenue driversFree High-Return Strategy Alerts - jammulinksnews.com
Stryker Corp. stock outperforms competitors on strong trading day - MarketWatch
A Look Into Stryker Inc's Price Over Earnings - Benzinga
Is Stryker Corporation a good long term investmentAccelerated capital growth - PrintWeekIndia
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
What drives Stryker Corporation stock priceHigh-yield growth strategies - Autocar Professional
Stryker Corporation Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What analysts say about Stryker Corporation stockFree Wealth Planning Blueprint - jammulinksnews.com
Stryker Corporation's (NYSE:SYK) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛
Lobbying Update: $230,000 of STRYKER CORPORATION lobbying was just disclosed - Quiver Quantitative
ISRG vs. SYK: Which Robotic Surgery Stock Is the Stronger Buy Today? - Yahoo Finance
Stryker's Consistent Growth and Market Positioning Justify Buy Rating - AInvest
Stryker Keeps Growing As Medical Device Demand Rises - Finimize
Rep. Thomas Kean Has Sold Up to $65K Worth Of Stryker Stock: Here's What You Should Know - Benzinga
David Driscoll discusses Stryker Corp - BNN Bloomberg
10 Best Health Care Stocks to Buy for 2025 | Investing - US News Money
Stryker (SYK) Faces New Competition in Robotics | SYK Stock News - GuruFocus
Stryker (SYK) Secures $450 Million Defense Contract Extension - GuruFocus
Stryker (SYK) Secures $450M Military Equipment Contract Extensio - GuruFocus
FDA Green Lights Stryker’s Incompass™ Total Ankle System - Orthopedics This Week
Stryker (SYK) Price Target Raised by BTIG Amid Mixed MedTech Sen - GuruFocus
What to Expect From Stryker's Next Quarterly Earnings Report - MSN
Looking Into Stryker's Recent Short Interest - 富途牛牛
North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key CompaniesOlympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies - Yahoo Finance
Blood Lead Analyzer Market Outlook 2025-2034 | Stryker Launches Advanced Pediatric ESIN Systems, Orthofix and Smith & Nephew Follow Suit - Yahoo Finance
What To Expect From Stryker's Next Quarterly Earnings Report - Barchart.com
Is Now The Time To Look At Buying Stryker Corporation (NYSE:SYK)? - 富途牛牛
Stryker’s Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy - Insider Monkey
Boston Scientific Sues Stryker Over Back Pain Treatment Patent - Bloomberg Law News
Here's How Much You Would Have Made Owning Stryker Stock In The Last 5 Years - Benzinga
Stryker to Report Second Quarter Fiscal Year 2025 Financial Results on July 31, 2025 - Quiver Quantitative
Stryker Earnings: When and How to Access Q2 2025 Financial Results and Live Webcast - Stock Titan
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System - Yahoo Finance
Stryker names Mike Carlin as leader of digital, robotics unit - Yahoo Finance
Ex-Dividend Reminder: National Healthcare, Stryker and Agree Realty - Nasdaq
Stryker makes leadership changes in digital, robotics business - MassDevice
Stryker receives FDA clearance for new total ankle replacement system - Investing.com
Moody’s upgrades Stryker Corporation to A3, outlook stable - Investing.com
Stryker Beats Sales Worker’s Military, Medical Leave Bias Claims - Bloomberg Law News
Stryker (SYK): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Stryker’s SWOT analysis: medical tech giant eyes growth amid challenges By Investing.com - Investing.com Canada
Stryker’s SWOT analysis: medical tech giant eyes growth amid challenges - Investing.com
Stryker Corp Stock (SYK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):